218 patents
Page 3 of 11
Utility
Topical formulation for a JAK inhibitor
28 Feb 23
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Filed: 25 Mar 22
Utility
Ruxolitinib formulation for reduction of itch in atopic dermatitis
28 Feb 23
This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.
Michael Kuligowski, Kang Sun, Michael Howell, May Grace E. Venturanza, Jim Lee
Filed: 28 Mar 22
Utility
Topical treatment of vitiligo by a jak inhibitor
28 Feb 23
The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Kathleen Butler, Jim Lee, Kang Sun, Fiona Kuo, Michael Howell
Filed: 8 Jul 22
Utility
Bipyrazole derivatives as JAK inhibitors
28 Feb 23
Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
Filed: 13 Apr 21
Utility
Bicyclic heterocycles as FGFR inhibitors
28 Feb 23
Oleg Vechorkin, Chao Qi, Minh Nguyen, Anlai Wang, Wenqing Yao
Filed: 8 Jul 20
Utility
Pyrrolotriazine compounds as TAM inhibitors
28 Feb 23
Yun-Long Li, Xiaozhao Wang, Chunhong He
Filed: 19 Oct 20
Utility
Biomarkers for inflammatory skin disease
21 Feb 23
Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor.
Michael D. Howell, Huiqing Liu
Filed: 29 Mar 19
Utility
Sustained-release dosage forms of ruxolitinib
14 Feb 23
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
Filed: 23 Jun 22
Utility
Sustained-release dosage forms of ruxolitinib
14 Feb 23
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
Filed: 23 Jun 22
Utility
Topical formulation for a JAK inhibitor
7 Feb 23
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Filed: 25 Mar 22
Utility
Heterocyclic compounds as immunomodulators
7 Feb 23
Jingwei Li, Liangxing Wu, Wenqing Yao
Filed: 24 Aug 20
Utility
Heterocyclic compounds as immunomodulators
31 Jan 23
Liangxing Wu, Bo Shen, Meizhong Xu, Wenqing Yao
Filed: 15 Sep 20
Utility
Bicyclic heterocycles as FGFR inhibitors
31 Jan 23
Artem Shvartsbart, Jeremy Roach, Wenqing Yao
Filed: 15 Oct 20
Utility
Pyrazolopyrimidine compounds and uses thereof
3 Jan 23
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Oleg Vechorkin, Kai Liu, Jun Pan, Alexander Sokolsky, Hai Fen Ye, Qinda Ye, Wenqing Yao, Joshua Hummel
Filed: 23 Apr 21
Utility
Heterocyclic compounds as immunomodulators
27 Dec 22
Neil Lajkiewicz, Liangxing Wu, Wenqing Yao
Filed: 11 Sep 20
Utility
Bicyclic heterocycles as FGFR inhibitors
20 Dec 22
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
Liang Lu, Wenqing Yao, Chunhong He, Fenglei Zhang
Filed: 28 Jan 21
Utility
Spiro compounds as inhibitors of KRAS
20 Dec 22
Disclosed are spirocyclic compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and treating cancer, and pharmaceutical compositions comprising such compounds.
Le Zhao, Xiaozhao Wang, Wenyu Zhu, Haolin Yin, Liangxing Wu, Wenqing Yao
Filed: 20 Jan 21
Utility
Ruxolitinib formulation for reduction of itch in atopic dermatitis
29 Nov 22
This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.
Michael Kuligowski, Kang Sun, Michael Howell, May Grace E. Venturanza, Jim Lee
Filed: 4 Sep 20
Utility
Salts of an LSD1 inhibitor and processes for preparing the same
29 Nov 22
The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase.
Zhongjiang Jia, Wayne Han, Yongchun Pan, Timothy Martin, Jiacheng Zhou, Qun Li
Filed: 12 Mar 21
Utility
Salts of a Pim kinase inhibitor
22 Nov 22
The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
Zhongjiang Jia, Ganfeng Cao, Qiyan Lin, Yongchun Pan, Lei Qiao, Vaqar Sharief, Chongsheng Eric Shi, Michael Xia, Changsheng Zheng, Qun Li
Filed: 13 Jan 21